SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Yoghurt may help prevent bowel cancer
Wed June 19th - Men who eat yoghurt at least twice a week appear to have a reduced risk of developing adenomas in the bowel, researchers report today. More
Large study links atrial fibrillation to dementia
Wed June 19th - Patients with atrial fibrillation face a raised risk of going on to develop dementia, researchers warn today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Dismay as prostate drug remains restricted

Thursday June 7th, 2018

Specialists have reacted in dismay after the use of the prostate cancer drug abiraterone remained restricted in England.

The drug, discovered in London, should not be used as a first-line treatment for men with advanced prostate cancer, the National Institute for Health and Care Excellence ruled yesterday.

Under current guidelines, patients must receive standard hormone therapy before getting abiraterone.

The Institute for Cancer Research, which discovered it, pointed out that the European Medicines Agency has approved the drug as a first-line treatment for advanced prostate cancer.

The drug works by blocking the production of testosterone.

ICR chief executive Professor Paul Workman said: “Abiraterone has been a game changer for treatment of prostate cancer – extending the lives of men with the disease, and crucially sparing them the side-effects of conventional chemotherapy.

“I am disappointed that men with advanced prostate cancer will not be able to access abiraterone as a first-line treatment. We hope the manufacturer will be able to provide the data NICE needs as soon as possible so that the drug can be made available earlier in treatment.

“I’d also urge both parties to get together to discuss the price of abiraterone, as it is essential that those men who might benefit from earlier access to the drug do not miss out on the grounds of cost.

“It is particularly concerning that some men who are ineligible for the current first-line treatment, docetaxel, should be denied access to abiraterone – and I would urge NICE to consider availability of the drug for these patients as a matter of urgency.”

A NICE spokesperson said: “The NICE appraisal committee found the company’s economic model did not accurately reflect the treatment pathway for people with high-risk hormone-sensitive metastatic prostate cancer.

“And data comparing the clinical effectiveness of abiraterone plus ADT with current standard treatment (docetaxel plus ADT) has not been fully explored. Therefore, the committee concluded there is no plausible cost-effectiveness estimate for abiraterone plus ADT compared with docetaxel plus ADT.”

Tags: Cancer | Men's Health | NHS | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES